

Intensive Enfuvirtide-containing Antiretroviral Therapy A5173 Study



Intensive Enfuvirtide-containing Antiretroviral Therapy A5173: Study Design

Study Design: A5173


- **Background**: Single-arm, pilot study to evaluate whether intensive enfuvirtide-containing antiretroviral therapy leads to a decay in the latent reservoir of HIV-infected resting memory CD4 cells.
- Inclusion Criteria (n = 19)
 - Antiretroviral-naïve patients
 - CD4 ≥100 cells/mm³
 - HIV RNA ≥1,000 copies/mL
 - No drug resistance mutations by genotype
- Treatment Arms
 - ENF 90 mg BID + TDF 300 mg QD + (FTC 200 mg QD or 3TC 300 mg QD) + SQV 1000 mg BID + RTV 100 mg BID

Enfuvirtide + TDF + (FTC or 3TC) + Ritonavir + Saquinavir (n = 19)



Intensive Enfuvirtide-containing Antiretroviral Therapy A5173: Result

Week 48: Immunologic Response




Analysis Cohort = 9 patients who remained on ENF through 48 weeks and achieved HIV RNA <50 copies/mL. Comparison Cohort = 6 patients who had HIV RNA < 50 copies/mL but stopped ENF before 48 weeks.

Source: Gandhi RT, et al. J Infect Dis. 2010;201:293-6



Intensive Enfuvirtide-containing Antiretroviral Therapy A5173: Result

Week 48: Virologic Response



Analysis Cohort = 9 patients who remained on ENF through 48 weeks and achieved HIV RNA <50 copies/mL. Comparison Cohort = 6 patients who had HIV RNA < 50 copies/mL but stopped ENF before 48 weeks.

Source: Gandhi RT, et al. J Infect Dis. 2010;201:293-6



Intensive Enfuvirtide-containing Antiretroviral Therapy A5173: Result (Latent Reservoir Decay)

- Analysis Cohort consisted of 9 patients who had virologic suppression and continued enfuvirtide-containing ART for at least 48 weeks.
- Patients in the Analysis Cohort had a median of 4 latent-reservoir measurements each.
 - 4/9 patients had a slight decrease of the number of latently infected cells
 - 5/9 patients had a slight increase in the number of latently infected cells
- No evidence for decay of the latent reservoir in Analysis Cohort



Intensive Enfuvirtide-containing Antiretroviral Therapy A5173: Conclusions

Conclusions: "In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir."

Source: Gandhi RT, et al. J Infect Dis. 2010;201:293-6.



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.



